 |
27 Diseases |  |
6 Trials |
|
6 Trials |  |
718 News |  |
| 12345678» |
- | Adlyxin (lixisenatide) / Sanofi
Preclinical, Journal: Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF? /HO-1 signaling. (Pubmed Central) - Jun 15, 2024
/HO-1 signaling. The combined administration of LIX and TIC produced more significant effects than a single treatment.
- | Adlyxin (lixisenatide) / Sanofi
Journal: Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence. (Pubmed Central) - May 24, 2024
Nonetheless, the emergence of gastrointestinal adverse events underscores the need for careful monitoring and management. Further extensive trials are warranted to delineate lixisenatide's efficacy and safety profile, fostering collaborative efforts towards precision treatments in PD.
- Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi
TRIM (Poster Hall (West A4-B2); 801) - May 20, 2024 - Abstract #ADA2024ADA_2833;
GLP1RAs reduce weight-related outcomes in adolescents with Semaglutide being the most efficacious. RCTs with direct comparisons, pragmatic study design, longer follow-up (to generate or verify safety signals), and adiposity-related outcomes are needed to further guide the usage and choice of GLP1RAs.
- || Review, Journal: Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making? (Pubmed Central) - May 18, 2024
Exendin-4 (Bydureon), Liraglutide (Victoza, Saxenda) and Lixisenatide (Adlyxin), drugs that are on the market as treatments for diabetes, have shown clear effects in improving motor activity in patients with PD in phase II clinical trials...Two phase III trials testing the GLP-1 drug semaglutide (Wegovy, Ozempic, Rybelsus) are ongoing...Newer drugs that have been designed to enter the brain easier are being developed already show improved effects in preclinical studies compared with the older GLP-1 class drugs that had been developed to treat diabetes. The future looks bright for new treatments for AD and PD.
- || Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi
Review: Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A (Pubmed Central) - May 15, 2024
GLP-1 RA therapy did not alter amyloid-? and tau biomarkers nor show improvements in cognition but showed potential metabolic and neuroprotective benefits.
- ||| Journal, Adverse events: Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. (Pubmed Central) - May 2, 2024
With the current pharmacovigilance approach, no causality link between suicidal ideation and use of any GLP-1 RA can be inferred. There is a need for further research and vigilance in GLP-1 RA prescribing, particularly in patients with co-existing psychiatric disorders.
- || Adlyxin (lixisenatide) / Sanofi
Retrospective data, Review, Journal: The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials. (Pubmed Central) - Apr 22, 2024
Lixisenatide was found to significantly decrease BW and BMI in patients with type 2 DM and could be considered as a therapeutic option for those suffering from weight gain caused by other anti-diabetic agents. However, while prescribing Lixisenatide, careful consideration of patient-specific factors is recommended.
- || Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi
Review, Journal: GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease. (Pubmed Central) - Apr 17, 2024
Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies is also very promising, enhancing the possibility of adding GLP1-R agonists to the current armamentarium of drugs available for PD treatment.
- | Adlyxin (lixisenatide) / Sanofi
Journal: Trial of Lixisenatide in Early Parkinson's Disease. (Pubmed Central) - Apr 14, 2024
P2
Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
- EXPLORING GASTROINTESTINAL AND HEPATOBILIARY ADVERSE EVENTS IN GLP-1 RECEPTOR AGONISTS THERAPY: A LARGE COHORT RETROSPECTIVE STUDY (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_8265;
Our findings indicate that GLP-1 RAs do not show an increase in GI cancer risk which is a significant clinical takeaway. However, caution and vigilance remain key, especially considering that each GLP-1 RA formulation carries its own spectrum of gastrointestinal and hepatobiliary side effects.
- GASTROPARESIS RISK IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED GLP-1 RECEPTOR AGONISTS (145B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6224;
We conclude an association between GLP-1RA prescription and increased GP risk in patients with T2D in this large study. We propose ongoing long-term clinical monitoring and further research in patients with T2D who are prescribed GLP analogs.
- ASSOCIATION BETWEEN PERIOPERATIVE GLP-1 AGONIST USE AND POST OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING UPPER ENDOSCOPY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2812;
Among 1299 participants in the study sample, 41 (3.2%) were taking semaglutide, and 69 (5.3%) were taking any GLP-1 agonist (semaglutide, dulaglutide, liraglutide, lixisenatide, exenatide, albiglutide) or dual GLP-1/GIP receptor agonist (tirzeparide). This large data base study of more than 1000 patients does not show a statistically significant relationship between GLP-1 agonist use and retained gastric products, aspiration events or postoperative vomiting.
- INCIDENCE OF ASPIRATION PNEUMONITIS AND EMERGENT INTUBATION IN PATIENTS ON GLUCAGON-LIKE PEPTIDE-1 INHIBITORS UNDERGOING UPPER ENDOSCOPY AND COLONOSCOPY: A COMPARATIVE STUDY (143ABC - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2702;
Contrary to initial concerns, our study shows that GLP-1 agonists do not increase the risk of aspiration pneumonitis or the need for emergent intubation in patients who undergo endoscopic procedures. Further randomized trials are warranted to evaluate the incidence of such outcomes and evidence-based peri-procedural usage of these medications.
- BARIATRIC SURGERY VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A COMPARISON OF CARDIOVASCULAR OUTCOMES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1357;
This large retrospective study found BS to be associated with a lower risk of adverse cardiovascular events compared with GLP-1 RA therapy. Further studies are needed to corroborate these findings.
- IBD PATIENTS CONCOMITANTLY TREATED WITH GLP1 AGONISTS HAD FEWER HOSPITALIZATIONS AND DISEASE RELATED COMPLICATIONS: A US COHORT PROPENSITY-MATCHED STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1179;
Conclusion : Although is not possible to assess a causal relationship, the IBD patients who received GLP-1 agonists were at lower risk of hospitalizations, IBD-related complications and surgery. Future study is needed to investigate the potential metabolic and inflammatory impact of GLP-1 agonists in IBD.
- | Adlyxin (lixisenatide) / Sanofi, Trulicity (dulaglutide) / Eli Lilly
Trial completion: SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. (clinicaltrials.gov) - Feb 28, 2024
P=N/A, N=140, Completed, Sponsor: Jose Seijas Amigo
Future study is needed to investigate the potential metabolic and inflammatory impact of GLP-1 agonists in IBD. Active, not recruiting --> Completed
- ARTIFICIAL INTELLIGENCE ANALYSIS OF SOCIAL MEDIA POSTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_7573;
This study demonstrates the potential of AI to analyze social media data and generate insights on public perceptions of GLP-1RA. This may guide strategies for addressing barriers to GLP-1RA use and identification of new groups interested in using these medications to improve their health that may warrant further study.
- || Victoza (liraglutide) / Novo Nordisk, Adlyxin (lixisenatide) / Sanofi, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal, Metastases: Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 22, 2024
Despite the limited number of studies in each analysis, our study provides evidence supporting the safety and efficacy of GLP-1RAs among T2DM patients with advanced CKD and ESKD. While gastrointestinal side effects may occur, GLP-1RAs demonstrate significant improvements in blood glucose control, weight reduction, and potential benefit in cardiovascular outcomes.
- | Adlyxin (lixisenatide) / Sanofi
Journal: Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells. (Pubmed Central) - Jan 21, 2024
Lastly, following the knockdown of Nrf2, the protective function of lixisenatide on LPS-triggered MUC5AC release in 16HBE cells was significantly abrogated. Collectively, lixisenatide ameliorated LPS-induced expression of mucin and inflammation in bronchial epithelial cells by regulating Nrf2.
- | Retrospective data, Journal: Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. (Pubmed Central) - Jan 8, 2024
Collectively, lixisenatide ameliorated LPS-induced expression of mucin and inflammation in bronchial epithelial cells by regulating Nrf2. Starting shorter-acting GLP-1 RAs is associated with increased risks of GERD and its complications.
- | Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. (Pubmed Central) - Dec 17, 2023
Among Japanese patients with T2D, tirzepatide showed the greatest effectiveness in reducing HbA1c levels and inducing weight loss. The study provides evidence to guide GLP-1RA treatment strategies in Japanese patients with T2D.
- ||| Journal, Adverse events: The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration adverse event reporting system (FAERS). (Pubmed Central) - Dec 13, 2023
Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide...Disproportionate reporting of suicidal behavior, suicide attempts and completed suicide were not observed for any of the FDA-approved GLP-1 RAs. Using the Bradford Hill criteria however and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.
- || Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Review, Journal: Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists. (Pubmed Central) - Oct 3, 2023
No study has evidenced a specific GLP-1RA pathway that quenches ROS production. Here we summarize the effects of GLP-1RAs against ROS overproduction and discuss the putative efficacy of Exendin-4, Lixisenatide, and Liraglutide in treating dementia by decreasing ROS.
- | metformin / Generic mfg.
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model. (Pubmed Central) - Sep 25, 2023
Medications with effective control of HbA1c or BMI were associated with a significantly smaller disease burden (p?<?0.05). Loxenatide combined with metformin was identified as the most economical choice, while the long-term health benefits of patients taking the six GLP-1RAs are approximate.
- || Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal: The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis. (Pubmed Central) - Sep 18, 2023
Loxenatide combined with metformin was identified as the most economical choice, while the long-term health benefits of patients taking the six GLP-1RAs are approximate. No abstract available
- || metformin / Generic mfg.
Review, Journal: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. (Pubmed Central) - Sep 17, 2023
The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide...In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.
- | Victoza (liraglutide) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Journal: Risk factors and drug discovery for cognitive impairment in type 2 diabetes mellitus using artificial intelligence interpretation and graph neural networks. (Pubmed Central) - Sep 15, 2023
Finally, we discovered the mechanism of herbal medicine interventions in gut microbiota. The method based on Interpreting AI and GNN can identify the risk factors and potential drugs associated with T2DM-CI.
- Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson (C1-M4/C1-M5 (Ground floor)) - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1430;
P2
The method based on Interpreting AI and GNN can identify the risk factors and potential drugs associated with T2DM-CI. Two single-center phase II trials with other GLP-1R agonists (exenatide, liraglutide) have shown pilot beneficial effects on motor and non-motor outcomes in advanced PD.; In this multicenter phase II trial run at 21 centers of the French NS-Park/FCRIN network, patients with early PD (< 3 years since diagnosis) on stable symptomatic medications without motor complications were randomized to receive subcutaneous injections of 20
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. (Pubmed Central) - Aug 25, 2023
However, at an annual price of $1,871.9, it was cost-effective compared with dulaglutide, liraglutide, and lixisenatide...However, to achieve cost-effectiveness in comparison to placebo, further cost reduction of oral semaglutide is necessary. The estimated annual cost of $1,711.03 for oral semaglutide demonstrates a more cost-effective option than placebo, highlighting its potential value in the management of T2DM.
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Journal: Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-?B/TNF-? and TGF-?/Smad pathways. (Pubmed Central) - Jul 31, 2023
The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/17832.
- ||| Journal, Adverse events: Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. (Pubmed Central) - Jul 29, 2023
To the best of our knowledge, this is the first study documenting the misuse/abuse potential of semaglutide in comparison with other GLP1 analogues and the phentermine-topiramate combination. The current findings will need to be confirmed by further empirical investigations to fully understand the safety profile of those molecules.
- PN127. Breaking News: GLP-1 agonists, SGLT2 inhibitors, CNS Stimulants - Perioperative Implications (South: 205/206) - Jul 20, 2023 - Abstract #ASA2023ASA_664;
Examples of GLP-1 RAs include exenatide (twice-daily and extended-release once-weekly), lixisenatide (once-daily), liraglutide (once-daily), dulaglutide (once-weekly), semaglutide (once-weekly), and oral semaglutide (once-daily)...During this panel, our experts will dissect the multifaceted impact of these medications on anesthetic care and patient safety, offering a comprehensive overview of their perioperative implications. Join us as we navigate the forefront of medical innovation and its intricate connection to the world of anesthesia.
- || Review, Journal: Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. (Pubmed Central) - Jul 18, 2023
Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
- ||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: LixiPark: Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease (clinicaltrials.gov) - Jun 22, 2023
P2, N=156, Completed, Sponsor: University Hospital, Toulouse
We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies. Unknown status --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal: GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jun 19, 2023
GLP-1RAs, particularly longer-acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Enrollment open: The Effect of Lixisenatide on the Effect of Pituitary Hormones (clinicaltrials.gov) - Jun 12, 2023
P4, N=10, Recruiting, Sponsor: University of Tartu
Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR. Not yet recruiting --> Recruiting
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Journal: A Non-Structural Protein of Severe Acute Respiratory Syndrome Coronavirus 2 with a Potential Ability to Reduce Blood Glucose for Use in Controlling Type 2 Diabetes Mellitus. (Pubmed Central) - Jun 9, 2023
The nsp10 was structurally aligned with GoDrugBank therapeutic agents, and lixisenatide was found to have the most similar chemical structure...The molecular dynamics for the stability of the nsp10 and GLP1R binding in triplicate for 150 ns demonstrated that the nsp10-GLP1R remained bound for more than 80 ns. This study indicated that the nsp10 protein can be further studied to be used as an antidiabetic medication.
- || Review, Journal: Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes. (Pubmed Central) - May 30, 2023
GLP-1 RA were not associated with increased risk of atrial (odds ratio 0.963, 95% confidence interval 0.869-1.066; P 0.46) or ventricular arrhythmias and sudden cardiac death (odds ratio 0.895, 95% confidence interval 0.706-1.135; P 0.36). GLP-1 RA are associated with decreased all-cause and cardiovascular mortality, and no increased risk of atrial and ventricular arrhythmias and sudden cardiac death.
- Efficacy and Safety of Glucagon-Like Peptide 1 Analogs and Agonists (aGLP1) in Overweight/Obese Patients: a Systematic Review and an Updated Network Meta-Analysis (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1868;
Tirzepatide 15 mg appears to be the most effective aGLP1 for weight reduction while it is similar to other aGLP1 regarding acceptability and safety. Taspoglutide was remarkably inferior to other aGLP1 considering discontinuation risk.
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
New P4 trial: The Effect of Lixisenatide on the Effect of Pituitary Hormones (clinicaltrials.gov) - Apr 7, 2023
P4, N=10, Not yet recruiting, Sponsor: University of Tartu
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Journal: Effect of Lixisenatide on Natriuretic Peptides in People With Type 2 Diabetes And Recent Acute Coronary Syndrome: The ELIXA Trial. (Pubmed Central) - Mar 7, 2023
Taspoglutide was remarkably inferior to other aGLP1 considering discontinuation risk. No abstract available
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (clinicaltrials.gov) - Feb 16, 2023
P=N/A, N=5, Terminated, Sponsor: Erasme University Hospital
No abstract available N=50 --> 5 | Trial completion date: Jul 2022 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Feb 2023; Recruitment too slow
- ||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
It’s a similar story to why I wouldn’t use lixisenatide (if it wasn’t pulled from market this year) for CV risk reduction in DM2 despite other GLP-1 agonists showing CV benefit. (Twitter) - Jan 27, 2023
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Efficacy and safety of semaglutide for weight management: evidence from the STEP program. (Pubmed Central) - Jan 25, 2023
Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the treatment of type 2 diabetes since 2005 including exenatide (short- and extended-release), lixisenatide, liraglutide, dulaglutide, albiglutide, and semaglutide...The most common adverse events reported in STEP 1-5 were gastrointestinal events, which were transient, mild-to-moderate in severity, and typically resolved without permanent treatment discontinuation. This article reviews the data from STEP 1-5 and highlights clinically relevant findings for primary care providers.
- | Adlyxin (lixisenatide) / Sanofi, Trulicity (dulaglutide) / Eli Lilly
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR: SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=140, Active, not recruiting, Sponsor: Jose Seijas Amigo
This article reviews the data from STEP 1-5 and highlights clinically relevant findings for primary care providers. Recruiting --> Active, not recruiting | N=360 --> 140 | Trial completion date: Apr 2023 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
- ||| Journal, Adverse events, Real-world evidence, Real-world: Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. (Pubmed Central) - Dec 27, 2022
In addition, semaglutide had the greatest risk of nausea, diarrhea, vomiting, constipation, and pancreatitis, while liraglutide had the greatest risk of upper abdominal pain. Our study provided valuable evidence for selecting appropriate GLP-1 RAs to avoid the occurrence of GLP-1 RA-induced gastrointestinal AEs.
- ||| Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Effect of Lixisenatide on Natriuretic Peptides in People With #Type2Diabetes And Recent #AcuteCoronarySyndrome : The ELIXA Trial @HCGerstein et al #Diabetes, #Obesity and #Metabolism https://t.co/4yKrLd71AV (Twitter) - Dec 27, 2022
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
A DUAL GLP-1/GIP AGONIST PROTECTS AGAINST NEURODEGENERATION BETTER THAN SEMAGLUTIDE IN THE 6-OHDA RAT MODEL OF PARKINSON'S DISEASE (On-Demand Oral Gallery C) - Dec 23, 2022 - Abstract #ADPD2023ADPD_768;
Our study provided valuable evidence for selecting appropriate GLP-1 RAs to avoid the occurrence of GLP-1 RA-induced gastrointestinal AEs. However, recent phase 2 clinical trials have shown disease-modifying effects testing drugs that originally had been developed to treat diabetes, the GLP-1 receptor agonists exendin-4 (Bydureon
- || Review, Journal: Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. (Pubmed Central) - Dec 8, 2022
The narrative review draws the comparison of GLP-1 RA use between diabetic and nondiabetic individual in terms of cardiovascular and metabolic benefits and points out the direction of future clinical trials of GLP-1 RAs in nondiabetic individuals. The focus of the review is on GLP-1 RAs' preventive roles in nondiabetic individuals with cardiovascular disease, chronic kidney diseases, obesity, dyslipidaemia, hypertension, nonalcoholic fatty liver diseases, polycystic ovarian syndrome (PCOS), and perioperative complications of bariatric surgery, albeit in small studies and subset analysis of clinical trials of diabetic patients.
- || Review, Journal: Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. (Pubmed Central) - Dec 6, 2022
Herein, we reviewed the recent progress, both in preclinical studies and clinical trials, regarding these clinically used GLP-1R agonists in aging-related neurodegenerative diseases, mainly AD and PD. We stress the pleiotropic characteristics of GLP-1R agonists as repurposing drugs to target multiple pathological mechanisms and for use in the future for these devastating neurodegenerative conditions.